A few hearings next week might spark some interest. Assembly Health will be taking up Assemblyman David Chiu's timely AB 463, the Pharmaceutical Cost Transparency Act, which would require drug companies to reveal operational costs in order to better understand pricing for ultra-high-priced drugs.
